EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study

Noémie Lang, Aurélie Ayme, Chang Ming, Jean-Damien Combes, Victor N Chappuis, Alex Friedlaender, Aurélie Vuilleumier, José L Sandoval, Valeria Viassolo, Pierre O Chappuis, S Intidhar Labidi-Galy

Swiss Medical Weekly · 2023

DOI: 10.57187/smw.2023.40055 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Swiss Medical Weekly, 2023. Verfasst von Noémie Lang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Carriers of germline pathogenic variants of the BRCA1 gene (gBRCA1) tend to have a higher incidence of haematological toxicity upon exposure to chemotherapy. We hypothesised that the occurrence of agranulocytosis during the first cycle of (neo-)adjuvant chemotherapy (C1) in breast cancer (BC) patients could predict gBRCA1 pathogenic variants. PATIENTS AND METHODS: The study population included non-metastatic BC patients selected for genetic counselling at Hôpitaux Universitaires de Genève (Jan. 1998 to Dec. 2017) with available mid-cycle blood counts performed during C1. The BOADICEA and Manchester scoring system risk-prediction models were applied. The primary outcome was the predicted likelihood of harbouring gBRCA1 pathogenic variants among patients presenting agranulocytosis during C1. RESULTS: Three hundred seven BC patients were included: 32 (10.4%) gBRCA1, 27 (8.8%) gBRCA2, and 248 (81.1%) non-heterozygotes. Mean age at diagnosis was 40 years. Compared with non-heterozygotes, gBRCA1 heterozygotes more frequently had grade 3 BC (78.1%; p = 0.014), triple-negative subtype (68.8%; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansAdultFemaleRetrospective StudiesBRCA2 ProteinGerm-Line MutationGerm CellsBRCA1 Protein

Substanzen

BRCA2 ProteinBRCA1 protein, humanBRCA1 Protein

Autor:innen und Institutionen

  • Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
  • Department of Diagnostics, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
  • Department of Clinical Research, Faculty of Medicine, University of Basel, Basel, Switzerland.
  • Infections and Cancer Epidemiology Group, International Agency for Research on Cancer, Lyon, France.

Förderung

  • World Health Organization

Zitieren

APA

Lang, N., Ayme, A., Ming, C., Combes, J. D., Chappuis, V. N., Friedlaender, A., Vuilleumier, A., Sandoval, J. L., Viassolo, V., Chappuis, P. O., & Labidi-Galy, S. I. (2023). Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study. Swiss Medical Weekly. https://doi.org/10.57187/smw.2023.40055

Vancouver

Lang N, Ayme A, Ming C, Combes JD, Chappuis VN, Friedlaender A, et al. Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study. Swiss Medical Weekly. 2023. doi:10.57187/smw.2023.40055

BibTeX
@article{Lang2023,
  author = {Lang, Noémie and Ayme, Aurélie and Ming, Chang and Combes, Jean-Damien and Chappuis, Victor N and Friedlaender, Alex and Vuilleumier, Aurélie and Sandoval, José L and Viassolo, Valeria and Chappuis, Pierre O and Labidi-Galy, S Intidhar},
  title = {Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study},
  journal = {Swiss Medical Weekly},
  year = {2023},
  doi = {10.57187/smw.2023.40055}
}
Kostenlos starten →